Dash Bio has filed a notice of an exempt offering of securities to raise $30,000,022.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Dash Bio is raising up to $30,000,022.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Dash Bio
Dash Bio is a bioanalysis contract research organization (CRO) built from the ground up with a tech-first approach to radically improve the speed and reliability of drug development testing. The company focuses on delivering clinical and preclinical sample analysis in days instead of weeks or months, positioning itself as a faster, more transparent alternative to traditional bioanalysis providers. From its headquarters in Boston, Dash Bio leverages AI, robotics, and modern software to automate critical steps in bioanalysis, aiming to remove bottlenecks and accelerate development timelines without compromising quality. Its model emphasizes transparent pricing, with published rates and guaranteed timelines and outcomes so sponsors know exactly what to expect from their studies. With a stated mission to ensure that groundbreaking medicines reach patients faster, Dash Bio is building highly automated, GLP-compliant bioanalysis capabilities intended to fundamentally reinvent how drugs are brought to market.
To learn more, visit https://www.dash.bio/
LinkedIn: https://www.linkedin.com/company/dashbio
Contact:
Alexander Tallett, Co-Founder and Chief Operating Officer
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
